# # #
\bibliographystyle{nature} \nobibliography{master}
if (!(grepl("src", getwd())))
setwd("../../../../src")
source("fe_func.R")
source("bmi_load.R")
# R version
rvers <- version$version.string
# Python version
# pyvers <- system("python --version")
# pysurfvers <- system("pip freeze | grep pysurf")
#pyvers <- "2.7.13"
#pysurfvers <- "0.7"
pyplusvers <- system("pyv=$(python -V 2>&1); echo $pyv", intern=TRUE)
pysurfplusvers <- system("pip list | grep pysurf", intern=TRUE)
- Schizophrenia has long been considered a disorder of dysconnectivity in the brain
- Using graph theory, we computed statistical similarity networks for each individual (Fig figflowchart, figshrinkage) in two early-phase schizophrenia cohorts src_R[:session]{parse_n(“sz”)} {{{results((N = 82))}}} and in healthy controls src_R[:session]{parse_n(“hc”)} {{{results((N = 77))}}} and tested whether network architecture predicted treatment response
\captionsetup{justification=justified,width=.85\linewidth}
\captionsetup{justification=justified,width=.85\linewidth}
- Individual differences in the configuration of structural similarity networks explained a significant proportion of variance in treatment response (Fig. figplsbrains)
- Exploratory analysis: increased clustering and decreased network integration in patients compared to controls (Fig. figge)
\captionsetup{justification=justified,width=.8\linewidth}
\captionsetup{justification=justified,width=0.8\linewidth}
fe_freesurfer_graphsum_individual_2plots.pdf
- These data suggest a potential link between brain network morphology and clinical outcome in early-phase schizophrenia
\tiny Dr. Robinson has served as a consultant for Asubio, Otsuka, and Shire and has received grants from Bristol-Myers Squibb, Janssen, and Otsuka. Dr. Kane has served as a consultant for Alkermes, Eli Lilly, Forest, Forum, Genentech, Intracellular Therapies, Janssen, Johnson & Johnson, Lundbeck, Otsuka, Reviva, Roche, Sunovion, and Teva; he has received honoraria for lectures from Genentech, Janssen, Lundbeck, and Otsuka; and he is a shareholder in MedAvante and Vanguard Research Group. Dr. Lencz is a consultant for Genomind. Dr. Malhotra has served as a consultant for Forum Pharmaceuticals and has served on a scientific advisory board for Genomind. The other authors report no financial relationships with commercial interests.